The Lung Precision Platform: Optellum's AI-Powered Early Intervention for Deadliest Cancers

In the landscape of oncology, lung cancer occupies a uniquely tragic position. It remains the deadliest cancer worldwide, yet when caught early, survival rates can increase dramatically. The challenge lies in the silent progression of the disease nodules discovered incidentally on chest CT scans may be malignant, but distinguishing which require immediate intervention from those that can be safely monitored has historically relied on subjective clinician judgment. For radiologists and pulmonologists managing growing populations of at-risk patients, the gap between data and decision has profound consequences.

Optellum was founded to close this gap. Spun out of Oxford University's Computer Vision Laboratory in 2016, the company has built the world’s only FDA-cleared, UKCA/CE-marked, and reimbursable radiomics AI solution for lung cancer diagnosis. Headquartered in Oxford, United Kingdom, with a U.S. presence in Houston's Texas Medical Center Innovation Institute, the company is led by Chief Executive Officer Dr. Johnathan Watkins. Optellum's Virtual Nodule Clinic platform integrates seamlessly with electronic health records and picture archiving systems, using deep learning trained on the world's largest curated chest CT dataset to discover lung nodules, assess malignancy risk, and guide clinicians toward optimal care decisions. The platform has demonstrated real-world impact, including more than 71 percent increase in interventional procedures for suspicious nodules and over 50 percent reduction in time to diagnosis.

The company's revenue model is built on software-as-a-service subscriptions for its Virtual Nodule Clinic platform, sold to healthcare providers and health systems. Optellum generates income through annual contracts with hospitals, imaging centers, and integrated delivery networks, with pricing scaled by patient volume and deployment complexity. Additional revenue streams include partnerships with life science organizations for clinical development, research collaborations, and data licensing. The company's strategic partnerships with industry leaders including Intuitive, Johnson & Johnson, and GE Healthcare demonstrate the value of its technology across the healthcare ecosystem.

The FDA-Cleared AI for Clinical Confidence

Optellum's most distinctive competitive advantage is its regulatory clearance and reimbursement status, which provides the clinical confidence and financial viability that experimental AI tools cannot offer. The Optellum Lung Cancer Prediction AI is the only radiomics solution with FDA 510(k) clearance, UKCA and CE marking, and CMS reimbursement coverage, enabling health systems to adopt the technology with confidence that it will be reimbursed and that it meets the rigorous standards required for clinical use. For radiologists and pulmonologists, this validation provides the assurance needed to incorporate AI recommendations into diagnostic workflows. For Optellum, the regulatory moat creates significant barriers to entry for competitors and positions the company as the established leader in the lung nodule AI space.

The World's Largest Curated Chest CT Dataset

Optellum has assembled the world's largest collection of curated chest CT scans, enriched with millions of clinical data points, creating a training foundation that competitors cannot easily replicate. Through academic and clinical partnerships including the DART collaboration, the dataset spans diverse populations, imaging protocols, and outcomes, enabling the development of AI models that generalize across clinical settings. The company's technology stack leverages convolutional neural networks, radiomics feature extraction, and natural language processing to discover at-risk patients from unstructured reports and precisely characterize nodules. For health systems, this data advantage translates into AI that performs reliably on their populations. For Optellum, it creates a sustainable competitive advantage that deepens with each new data contribution from partner sites.

The Integrated Platform for End-to-End Lung Cancer Care

Optellum's Virtual Nodule Clinic provides a complete solution for lung nodule management, addressing the full care continuum from patient discovery through diagnosis and treatment. Patient Discovery AI automatically identifies individuals with nodules requiring follow-up. The Lung Cancer Prediction AI assesses malignancy risk with accuracy exceeding standard clinical models. Triage and tracking tools ensure that high-risk patients are prioritized and monitored appropriately. For oncology and life science partners, the platform extends to mass discovery and treatment support, with tumor dashboards that help clinicians identify candidates for neoadjuvant therapies. This end-to-end integration creates stickiness across the care pathway, making the platform indispensable to thoracic care teams and tumor boards.

The Real-World Impact Evidence for Value Demonstration

Optellum has generated compelling evidence of real-world impact that validates its value proposition to providers, payers, and partners. Published and in-preparation studies demonstrate more than 71 percent increases in interventional procedures for malignant nodules and over 50 percent reductions in time to diagnosis. For health systems facing lung cancer screening mandates and quality metrics, these outcomes translate directly into improved patient care and operational efficiency. For Optellum, the evidence base provides the data required to support contracting conversations with risk-averse health systems and to demonstrate return on investment for budget-constrained decision-makers.

For healthcare providers seeking to transform lung cancer diagnosis from a reactive process into a precision discipline, Optellum offers the AI platform that makes early intervention operationally achievable. Dr. Johnathan Watkins and his team have built an organization where regulatory clearance, unmatched data assets, integrated workflow solutions, and proven real-world impact combine to deliver the lung precision care platform for thoracic teams. With a presence in leading academic medical centers, partnerships across the life sciences industry, and a mission to ensure that every lung disease patient is diagnosed and treated at the earliest possible stage, Optellum stands as the essential partner for institutions ready to redefine early intervention.

Dr. Johnathan Watkins, Chief Executive Officer

"It’s about finding the patients, many of whom are asymptomatic, and accelerating their time to diagnosis, care and ultimately cure. Knowing earlier gives you and your healthcare provider the opportunity to intervene before treatment options are limited."